Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
RBC Capital to hold a virtual conference » 04:55
05/20/20
05/20
04:55
05/20/20
04:55
ADUS

Addus HomeCare

$89.04 /

-0.89 (-0.99%)

, HOOK

Hookipa Pharma

$9.27 /

-0.88 (-8.67%)

, KPTI

Karyopharm

$17.68 /

-0.97 (-5.20%)

, UHS

Universal Health

$101.01 /

+0.55 (+0.55%)

, ENTA

Enanta

$54.33 /

-3.25 (-5.64%)

, REGN

Regeneron

$557.61 /

-1.76 (-0.31%)

, ARAV

Aravive

$12.27 /

-0.31 (-2.46%)

, IMGN

ImmunoGen

$4.62 /

-0.14 (-2.94%)

, HCA

HCA Healthcare

$103.94 /

-1.63 (-1.54%)

, PFE

Pfizer

$37.68 /

-0.4 (-1.05%)

, BCEL

Atreca

$18.06 /

-0.69 (-3.68%)

, JAZZ

Jazz Pharmaceuticals

$113.07 /

-3.23 (-2.78%)

, OVID

Ovid Therapeutics

$4.46 /

+0.29 (+6.95%)

, ACAD

Acadia

$51.02 /

-1.05 (-2.02%)

, BMRN

BioMarin

$93.88 /

-1.46 (-1.53%)

, EHTH

eHealth

$124.65 /

-2.38 (-1.87%)

, EXEL

Exelixis

$24.87 /

-0.79 (-3.08%)

, INO

Inovio

$14.56 /

+0.41 (+2.90%)

, SPRT

Support.com

$1.25 /

-0.01 (-0.79%)

, CYH

Community Health

$3.11 /

-0.05 (-1.58%)

, INCY

Incyte

$94.92 /

-1.58 (-1.64%)

, AGIO

Agios Pharmaceuticals

$47.89 /

-0.93 (-1.90%)

, EGRX

Eagle Pharmaceuticals

$53.24 /

-1.26 (-2.31%)

, IGMS

IGM Biosciences

$52.75 /

-2.66 (-4.80%)

, AIMT

Aimmune

$16.55 /

-0.92 (-5.27%)

, VRCA

Verrica Pharmaceuticals

$10.11 /

-0.62 (-5.78%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 19-20.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

SPRT Support.com
$1.25 /

-0.01 (-0.79%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

ENTA Enanta
$54.33 /

-3.25 (-5.64%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

BCEL Atreca
$18.06 /

-0.69 (-3.68%)

ARAV Aravive
$12.27 /

-0.31 (-2.46%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

03/20/20 RBC Capital
RBC says Addus HomeCare selloff unwarranted as lockdowns don't apply
12/10/19 Oppenheimer
Addus HomeCare price target raised to $107 from $96 at Oppenheimer
11/21/19 RBC Capital
Addus HomeCare price target raised to $109 from $100 at RBC Capital
11/06/19 RBC Capital
Addus HomeCare price target raised to $100 from $90 at RBC Capital
HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
UHS Universal Health
$101.01 /

+0.55 (+0.55%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
ENTA Enanta
$54.33 /

-3.25 (-5.64%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
REGN Regeneron
$557.61 /

-1.76 (-0.31%)

05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
ARAV Aravive
$12.27 /

-0.31 (-2.46%)

04/30/20 Piper Sandler
Aravive partnering with WuXi to develop CCN2 antibodies, says Piper Sandler
03/27/20 H.C. Wainwright
Aravive price target lowered to $15 from $25 at H.C. Wainwright
02/18/20 Piper Sandler
IDMC recommends dose escalation in Aravive trial, says Piper Sandler
01/13/20 Piper Sandler
Piper Sandler reiterated Overweight on Aravive after AVB-500 expansion
IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

04/27/20 UBS
HCA Healthcare price target lowered to $138 from $183 at UBS
04/22/20 SunTrust
HCA Healthcare price target lowered to $140 from $160 at SunTrust
04/22/20 Deutsche Bank
HCA Healthcare price target lowered to $132 from $165 at Deutsche Bank
04/22/20 Oppenheimer
HCA Healthcare price target lowered to $135 from $160 at Oppenheimer
PFE Pfizer
$37.68 /

-0.4 (-1.05%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
05/15/20 William Blair
Sarepta maintains leadership position after Pfizer data, says William Blair
BCEL Atreca
$18.06 /

-0.69 (-3.68%)

04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/15/20 Baird
Atreca initiated with an Outperform at Baird
JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
ACAD Acadia
$51.02 /

-1.05 (-2.02%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
EHTH eHealth
$124.65 /

-2.38 (-1.87%)

05/14/20 Raymond James
Raymond James says eHealth accounting more conservative than some peers
05/14/20 Craig-Hallum
CMS' SEP to be like new Easter season for eHealth, says Craig-Hallum
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
04/24/20 SunTrust
eHealth's path to over 50% growth has been made easier, says SunTrust
EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
INO Inovio
$14.56 /

+0.41 (+2.90%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
SPRT Support.com
$1.25 /

-0.01 (-0.79%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

02/24/20 RBC Capital
Community Health price target raised to $8 from $4 at RBC Capital
02/20/20 Raymond James
Community Health upgraded at Raymond James as near-term pressures limited
02/20/20 Raymond James
Community Health upgraded to Market Perform from Underperform at Raymond James
INCY Incyte
$94.92 /

-1.58 (-1.64%)

05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Piper Sandler
IGM Biosciences price target raised to $81 from $53 at Piper Sandler
04/22/20 Wedbush
Wedbush bullish on IGM Biosciences, initiates with an Outperform
AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
03/23/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
11/27/19 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $23 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

ENTA Enanta
$54.33 /

-3.25 (-5.64%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

BCEL Atreca
$18.06 /

-0.69 (-3.68%)

ARAV Aravive
$12.27 /

-0.31 (-2.46%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

SPRT Support.com
$1.25 /

-0.01 (-0.79%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

Over a week ago
Conference/Events
RBC Capital to hold a virtual conference » 08:45
05/19/20
05/19
08:45
05/19/20
08:45
ADUS

Addus HomeCare

$89.93 /

+5.99 (+7.14%)

, HOOK

Hookipa Pharma

$10.15 /

+0.78 (+8.32%)

, KPTI

Karyopharm

$18.65 /

-0.4 (-2.10%)

, UHS

Universal Health

$100.46 /

+7.86 (+8.49%)

, ENTA

Enanta

$57.58 /

+2.25 (+4.07%)

, REGN

Regeneron

$559.37 /

-16.71 (-2.90%)

, ARAV

Aravive

$12.58 /

+0.11 (+0.88%)

, IMGN

ImmunoGen

$4.76 /

+0.33 (+7.45%)

, HCA

HCA Healthcare

$105.57 /

+6.83 (+6.92%)

, PFE

Pfizer

$38.08 /

+0.31 (+0.82%)

, BCEL

Atreca

$18.75 /

-0.44 (-2.29%)

, JAZZ

Jazz Pharmaceuticals

$116.30 /

+4.79 (+4.30%)

, OVID

Ovid Therapeutics

$4.17 /

+0.09 (+2.21%)

, ACAD

Acadia

$52.07 /

+1.23 (+2.42%)

, BMRN

BioMarin

$95.34 /

+1.595 (+1.70%)

, EHTH

eHealth

$127.03 /

+9.13 (+7.74%)

, EXEL

Exelixis

$25.66 /

-0.07 (-0.27%)

, INO

Inovio

$14.15 /

+0.73 (+5.44%)

, SPRT

Support.com

$1.26 /

+0.06 (+5.00%)

, CYH

Community Health

$3.16 /

+0.435 (+15.99%)

, INCY

Incyte

$96.50 /

+0.37 (+0.38%)

, AGIO

Agios Pharmaceuticals

$48.82 /

+2.38 (+5.12%)

, EGRX

Eagle Pharmaceuticals

$54.50 /

+1.74 (+3.30%)

, IGMS

IGM Biosciences

$55.41 /

-3.59 (-6.08%)

, AIMT

Aimmune

$17.47 /

+1.1 (+6.72%)

, VRCA

Verrica Pharmaceuticals

$10.73 /

+0.47 (+4.58%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 19-20.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

SPRT Support.com
$1.26 /

+0.06 (+5.00%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

ENTA Enanta
$57.58 /

+2.25 (+4.07%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

BCEL Atreca
$18.75 /

-0.44 (-2.29%)

ARAV Aravive
$12.58 /

+0.11 (+0.88%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

03/20/20 RBC Capital
RBC says Addus HomeCare selloff unwarranted as lockdowns don't apply
12/10/19 Oppenheimer
Addus HomeCare price target raised to $107 from $96 at Oppenheimer
11/21/19 RBC Capital
Addus HomeCare price target raised to $109 from $100 at RBC Capital
11/06/19 RBC Capital
Addus HomeCare price target raised to $100 from $90 at RBC Capital
HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
UHS Universal Health
$100.46 /

+7.86 (+8.49%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
ENTA Enanta
$57.58 /

+2.25 (+4.07%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
REGN Regeneron
$559.37 /

-16.71 (-2.90%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
ARAV Aravive
$12.58 /

+0.11 (+0.88%)

04/30/20 Piper Sandler
Aravive partnering with WuXi to develop CCN2 antibodies, says Piper Sandler
03/27/20 H.C. Wainwright
Aravive price target lowered to $15 from $25 at H.C. Wainwright
02/18/20 Piper Sandler
IDMC recommends dose escalation in Aravive trial, says Piper Sandler
01/13/20 Piper Sandler
Piper Sandler reiterated Overweight on Aravive after AVB-500 expansion
IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

04/27/20 UBS
HCA Healthcare price target lowered to $138 from $183 at UBS
04/22/20 SunTrust
HCA Healthcare price target lowered to $140 from $160 at SunTrust
04/22/20 Deutsche Bank
HCA Healthcare price target lowered to $132 from $165 at Deutsche Bank
04/22/20 Oppenheimer
HCA Healthcare price target lowered to $135 from $160 at Oppenheimer
PFE Pfizer
$38.08 /

+0.31 (+0.82%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
05/15/20 William Blair
Sarepta maintains leadership position after Pfizer data, says William Blair
BCEL Atreca
$18.75 /

-0.44 (-2.29%)

04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/15/20 Baird
Atreca initiated with an Outperform at Baird
JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
ACAD Acadia
$52.07 /

+1.23 (+2.42%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
EHTH eHealth
$127.03 /

+9.13 (+7.74%)

05/14/20 Raymond James
Raymond James says eHealth accounting more conservative than some peers
05/14/20 Craig-Hallum
CMS' SEP to be like new Easter season for eHealth, says Craig-Hallum
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
04/24/20 SunTrust
eHealth's path to over 50% growth has been made easier, says SunTrust
EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
INO Inovio
$14.15 /

+0.73 (+5.44%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
SPRT Support.com
$1.26 /

+0.06 (+5.00%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

02/24/20 RBC Capital
Community Health price target raised to $8 from $4 at RBC Capital
02/20/20 Raymond James
Community Health upgraded at Raymond James as near-term pressures limited
02/20/20 Raymond James
Community Health upgraded to Market Perform from Underperform at Raymond James
INCY Incyte
$96.50 /

+0.37 (+0.38%)

05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Piper Sandler
IGM Biosciences price target raised to $81 from $53 at Piper Sandler
04/22/20 Wedbush
Wedbush bullish on IGM Biosciences, initiates with an Outperform
AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
03/23/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
11/27/19 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $23 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

ENTA Enanta
$57.58 /

+2.25 (+4.07%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

BCEL Atreca
$18.75 /

-0.44 (-2.29%)

ARAV Aravive
$12.58 /

+0.11 (+0.88%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

SPRT Support.com
$1.26 /

+0.06 (+5.00%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

Recommendations
Incyte price target raised to $100 from $83 at Cantor Fitzgerald » 07:55
05/19/20
05/19
07:55
05/19/20
07:55
INCY

Incyte

$96.50 /

+0.37 (+0.38%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Alethia Young raised the firm's price target on Incyte to $100 from $83 and keeps a Neutral rating on the shares to include tafasitamab in her base case along with the appropriate accounting. Young says the company remains very defensive and has only seen some COVID-19 disruptions in certain areas like New York and thinks this is attributable to Jakafi as an oral agent that is very established in the marketplace. Young believes the company is set up well for the year and thinks tafasitamab could have blockbuster potential over time.

ShowHide Related Items >><<
INCY Incyte
$96.50 /

+0.37 (+0.38%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
05/06/20 RBC Capital
Incyte price target raised to $91 from $81 at RBC Capital
INCY Incyte
$96.50 /

+0.37 (+0.38%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

Hot Stocks
MorphoSys announces long-term follow-up results from L-MIND study of tafasitamab » 09:54
05/14/20
05/14
09:54
05/14/20
09:54
MOR

MorphoSys

$30.68 /

+ (+0.00%)

, INCY

Incyte

$96.14 /

-0.31 (-0.32%)

MorphoSys (MOR) and…

MorphoSys (MOR) and Incyte (INCY) reported updated results from the ongoing Phase 2 L-MIND study investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, or r/r DLBCL. The results, based on a November 30, 2019 data cut-off, corroborate previously reported primary analysis data, the companies said. In this long-term analysis of the L-MIND data, 80 study patients receiving tafasitamab plus lenalidomide were included in the efficacy analysis. After a minimum of two years' follow-up, outcomes from the L-MIND study are consistent with the primary analysis and confirm the durability of the response and overall survival of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in autologous stem cell transplantation-ineligible patients with r/r DLBCL. Assessment by an independent review committee at data cut-off showed an objective response rate of 58.8%, or 47 out of 80 patients, and a complete response rate of 41.3%, or 33 out of 80 patients. Median duration of response was 34.6 months, with median overall survival of 31.6 months and median progression-free survival of 16.2 months. The safety profile was consistent with that observed in previously reported studies of tafasitamab in combination with lenalidomide. The full analysis will be presented virtually at the EHA Annual Congress to be held June 11-14.

ShowHide Related Items >><<
MOR MorphoSys
$30.68 /

+ (+0.00%)

INCY Incyte
$96.14 /

-0.31 (-0.32%)

MOR MorphoSys
$30.68 /

+ (+0.00%)

05/13/20 Barclays
MorphoSys price target raised to EUR 105 from EUR 100 at Barclays
05/12/20 HSBC
MorphoSys upgraded to Hold from Reduce at HSBC
03/25/20 Oppenheimer
Incyte price target lowered to $85 from $99 at Oppenheimer
03/11/20 Credit Suisse
Incyte price target lowered to $81 from $86 at Credit Suisse
INCY Incyte
$96.14 /

-0.31 (-0.32%)

05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
05/06/20 RBC Capital
Incyte price target raised to $91 from $81 at RBC Capital
MOR MorphoSys
$30.68 /

+ (+0.00%)

INCY Incyte
$96.14 /

-0.31 (-0.32%)

MOR MorphoSys
$30.68 /

+ (+0.00%)

INCY Incyte
$96.14 /

-0.31 (-0.32%)

INCY Incyte
$96.14 /

-0.31 (-0.32%)

Recommendations
Incyte approval of Tabrecta came soon than expected, says Piper Sandler » 16:28
05/06/20
05/06
16:28
05/06/20
16:28
INCY

Incyte

$96.05 /

-2.89 (-2.92%)

, NVS

Novartis

$85.34 /

+0.56 (+0.66%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren noted that Incyte (INCY) announced FDA approval of Tabrecta in METex14 non-small cell lung cancer "well ahead" of the PDUFA date scheduled in August. Tabrecta is the first oral MET inhibitor approved and its label "is relatively clean" and does not concern him given the low rates of treatment discontinuation, Van Buren added. The drug was also approved for use regardless of line of therapy, said the analyst, who "conservatively" estimates Tabrecta sales topping $500M by the mid-2020s with royalties to Incyte from partner Novartis (NVS) approaching $100M. Van Buren keeps an Overweight rating on Incyte shares.

ShowHide Related Items >><<
INCY Incyte
$96.05 /

-2.89 (-2.92%)

05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
05/06/20 RBC Capital
Incyte price target raised to $91 from $81 at RBC Capital
05/06/20 JPMorgan
Incyte downgraded to Neutral on valuation at JPMorgan
NVS Novartis
$85.34 /

+0.56 (+0.66%)

04/29/20 JPMorgan
Novartis price target lowered to CHF 84 from CHF 91 at JPMorgan
04/29/20 Barclays
Novartis price target raised to CHF 75 from CHF 70 at Barclays
04/27/20 Stifel
Global Blood Therapeutics initiated with a Buy at Stifel
04/23/20 Morgan Stanley
Novartis price target lowered to CHF 91 from CHF 93 at Morgan Stanley
Hot Stocks
Incyte announces FDA accelerated approval of Tabrecta » 14:43
05/06/20
05/06
14:43
05/06/20
14:43
INCY

Incyte

$96.49 /

-2.45 (-2.48%)

, NVS

Novartis

$85.85 /

+1.07 (+1.26%)

Incyte (INCY) announced…

Incyte (INCY) announced that the U.S. Food and Drug Administration has approved Tabrecta for treatment of adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s), the company said. "Tabrecta, the first and only treatment approved to specifically target NSCLC with this driver mutation, is approved for first-line and previously treated patients regardless of prior treatment type," Incyte noted. Novartis (NVS) has exclusive worldwide development and commercialization rights to Tabrecta, and the FDA approval of Tabrecta triggers $70M in milestone payments from Novartis to Incyte. Incyte is also eligible to receive 12-14% royalties on net sales of Tabrecta by Novartis, the company reported.

ShowHide Related Items >><<
INCY Incyte
$96.49 /

-2.45 (-2.48%)

05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
05/06/20 RBC Capital
Incyte price target raised to $91 from $81 at RBC Capital
05/06/20 JPMorgan
Incyte downgraded to Neutral on valuation at JPMorgan
NVS Novartis
$85.85 /

+1.07 (+1.26%)

04/29/20 JPMorgan
Novartis price target lowered to CHF 84 from CHF 91 at JPMorgan
04/29/20 Barclays
Novartis price target raised to CHF 75 from CHF 70 at Barclays
04/27/20 Stifel
Global Blood Therapeutics initiated with a Buy at Stifel
04/23/20 Morgan Stanley
Novartis price target lowered to CHF 91 from CHF 93 at Morgan Stanley
Downgrade
Fly Intel: Top five analyst downgrades » 10:08
05/06/20
05/06
10:08
05/06/20
10:08
SNAP

Snap

$17.55 /

+0.03 (+0.17%)

, TRIP

TripAdvisor

$18.48 /

+0.13 (+0.71%)

, INCY

Incyte

$96.82 /

-2.12 (-2.14%)

, DOW

Dow Inc.

$33.02 /

-0.37 (-1.11%)

, TRI

Thomson Reuters

$69.48 /

-0.35 (-0.50%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Snap (SNAP) downgraded to Sell from Neutral at Citi with analyst Jason Bazinet saying investor expectations for 2020 and 2021 revenues are too high. 2. TripAdvisor (TRIP) downgraded to Hold from Buy at Deutsche Bank with analyst Lloyd Walmsley saying he sees "some slightly signs" of a pickup in booking intent in the U.S., but his confidence in the pace of recovery in travel over the medium term is now lower than it was in early March. 3. Incyte (INCY) downgraded to Neutral from Overweight at JPMorgan with analyst Cory Kasimov saying Incyte continues to make good progress with its flagship commercial franchise, but the shares are up nearly 60% from the lows of late March. 4. Dow Inc. (DOW) downgraded to Neutral from Buy at UBS with analyst John Roberts saying he sees a more balanced risk/reward at current share levels. 5. Thomson Reuters (TRI) downgraded to Hold from Buy at TD Securities with analyst Vince Valentini saying he acknowledges the strength of Thomson Reuters' business model and "rock-solid" balance sheet but says he "just cannot ignore valuation." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
SNAP Snap
$17.55 /

+0.03 (+0.17%)

05/06/20 Citi
Snap downgraded to Sell from Neutral at Citi
04/27/20 JMP Securities
Facebook Q1 should benefit from same headwinds as Snap, says JMP Securities
04/23/20 Rosenblatt
Snap price target raised to $18 from $14 at Rosenblatt
04/22/20 SunTrust
Snap price target raised to $15 from $12 at SunTrust
TRIP TripAdvisor
$18.48 /

+0.13 (+0.71%)

05/06/20 Cleveland Research
TripAdvisor checks remain 'quite cautious,' says Cleveland Research
05/06/20 Deutsche Bank
Deutsche downgrades TripAdvisor on lack of confidence in travel rebound
05/06/20 Deutsche Bank
TripAdvisor downgraded to Hold from Buy at Deutsche Bank
05/05/20 Needham
TripAdvisor price target lowered to $26 from $39 at Needham
INCY Incyte
$96.82 /

-2.12 (-2.14%)

05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
05/06/20 RBC Capital
Incyte price target raised to $91 from $81 at RBC Capital
05/06/20 JPMorgan
Incyte downgraded to Neutral on valuation at JPMorgan
05/05/20 JPMorgan
Incyte downgraded to Neutral from Overweight at JPMorgan
DOW Dow Inc.
$33.02 /

-0.37 (-1.11%)

05/06/20 UBS
Dow Inc. downgraded to Neutral from Buy at UBS
05/04/20
Fly Intel: Top five analyst downgrades
05/04/20 SunTrust
Dow Inc. price target lowered to $37 from $47 at SunTrust
05/04/20 BofA
LyondellBasell downgraded to Underperform from Neutral at BofA
TRI Thomson Reuters
$69.48 /

-0.35 (-0.50%)

05/06/20
Fly Intel: Top five analyst upgrades
05/06/20 TD Securities
TD downgrades Thomson Reuters on valuation following BMO upgrade
05/06/20 TD Securities
Thomson Reuters downgraded to Hold from Buy at TD Securities
05/05/20 BMO Capital
Thomson Reuters upgraded to Outperform from Market Perform at BMO Capital
Recommendations
Incyte price target raised to $120 from $112 at Oppenheimer » 08:10
05/06/20
05/06
08:10
05/06/20
08:10
INCY

Incyte

$98.94 /

-2.32 (-2.29%)

Oppenheimer analyst Jay…

Oppenheimer analyst Jay Olson raised the firm's price target on Incyte to $120 from $112 and keeps an Outperform rating on the shares. The analyst notes that the company reported Q1 results with topline growth despite COVID-19 while maintaining previous fiscal year 2020 revenue and OpEx guidance.

ShowHide Related Items >><<
INCY Incyte
$98.94 /

-2.32 (-2.29%)

05/06/20 RBC Capital
Incyte price target raised to $91 from $81 at RBC Capital
05/06/20 JPMorgan
Incyte downgraded to Neutral on valuation at JPMorgan
05/05/20 JPMorgan
Incyte downgraded to Neutral from Overweight at JPMorgan
05/05/20 Piper Sandler
Incyte share strength to continue after 'strong' Q1, says Piper Sandler
Recommendations
Incyte price target raised to $91 from $81 at RBC Capital » 07:08
05/06/20
05/06
07:08
05/06/20
07:08
INCY

Incyte

$98.94 /

-2.32 (-2.29%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams raised the firm's price target on Incyte to $91 from $81 but keeps a Sector Perform rating on the shares. The analyst cites the company's strong Q1 Jakafi growth and no COVID-related disruptions in the near term, though from here, he sees shares trading in-line pending improved visibility on the medium-term commercial opportunity and a longer-term Jakafi life cycle plan.

ShowHide Related Items >><<
INCY Incyte
$98.94 /

-2.32 (-2.29%)

05/06/20 JPMorgan
Incyte downgraded to Neutral on valuation at JPMorgan
05/05/20 JPMorgan
Incyte downgraded to Neutral from Overweight at JPMorgan
05/05/20 Piper Sandler
Incyte share strength to continue after 'strong' Q1, says Piper Sandler
04/29/20 Morgan Stanley
Incyte downgraded to Equal Weight following 35% rally at Morgan Stanley
Downgrade
Incyte downgraded to Neutral on valuation at JPMorgan » 05:56
05/06/20
05/06
05:56
05/06/20
05:56
INCY

Incyte

$98.94 /

-2.32 (-2.29%)

JPMorgan analyst Cory…

JPMorgan analyst Cory Kasimov downgraded Incyte to Neutral from Overweight with a price target of $99, up from $89. Incyte continues to make good progress with its flagship commercial franchise, but the shares are up nearly 60% from the lows of late March, Kasimov tells investors in a research note. The analyst cites valuation for moving to the sidelines.

ShowHide Related Items >><<
INCY Incyte
$98.94 /

-2.32 (-2.29%)

05/05/20 JPMorgan
Incyte downgraded to Neutral from Overweight at JPMorgan
05/05/20 Piper Sandler
Incyte share strength to continue after 'strong' Q1, says Piper Sandler
04/29/20 Morgan Stanley
Incyte downgraded to Equal Weight following 35% rally at Morgan Stanley
04/29/20 Morgan Stanley
Incyte downgraded to Equal Weight from Overweight at Morgan Stanley

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.